Arterial Stiffness
Conditions
Keywords
risk factors, cohort, cardiovascular diseases
Brief summary
The main objectives of PPS3-2 are (i) to describe the dynamics of vascular aging and baroreflex sensitivity 12 to 16 years a part, (ii) to identify their determinants, and (iii) to quantify the subsequent risk of cardiovascular diseases.
Detailed description
Since May 2008, PPS3 is being following the CVD morbidity of 10157 healthy volunteers aged 50-75 years at baseline. In PPS3-2, we plan to re-invite survivors and volunteers of PPS3 to undergo a second physical examination. In particular, they will undergo a second high-precision carotid echotracking to measure vascular aging parameters and baroreflex sensitivity, permitting to study their respective dynamics. They will also underwent for the first time ultra fast echo of the radial artery to measure vascular aging parameters of the medium-sized arteries. According to fundings, blood samples will be taken and stored at -80°C in the whole population or in a subsample.
Interventions
OTHERhigh-precision carotid echo-tracking
evaluation of vascular aging parameters and baroreflex sensitivity
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to 95 Years
Healthy volunteers
Yes
Inclusion criteria
* Being enrolled in PPS3 and having signed an informed consent for PPS3-2
Exclusion criteria
* Institutionalized participants * Participants under guardianship * Participants under judicial safeguard measure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| carotid diameter | by 2027 | high precision carotid echo tracking diameter in mm |
| intima media thickness | by 2027 | high precision echo tracking intima media thickness of the common carotid artery in mm |
| carotid plaques | by 2027 | high precision carotid echo tracking carotid plaques |
| wall cross sectional area | by 2027 | high precision carotid echo tracking carotid wall cross sectional area, mm2 |
| distensibility coefficient | by 2027 | high precision carotid echo tracking distensibility coefficient in 10-3/kPa |
| elastic modulus | by 2027 | high precision carotid echo tracking Young's elastic modulus, 10-3\*kPa |
| pulse wave velocity | by 2027 | high precision carotid echotracking pulse wave velocity, m/s |
| carotid wall stress | by 2027 | high precision carotid echotracking circumferential wall stress in kPa |
| stiffness | by 2027 | high precision carotid echotracking Beta stiffness index |
| pulse pressure | by 2027 | high precision carotid echotracking pulse pressure in mmHg |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| brachial artery diameter | by 2027 | ultra high frequency ultrasound radial artery diameter in mm |
| thickness of the intima media of the radial artery | by 2027 | ultra high frequency ultrasound radial artery intima media thickness in mm |
| arterial plaques | by 2027 | ultra high frequency ultrasound radial artery plaques |
| wall cross sectional area of the radial artery | by 2027 | ultra high frequency ultrasound radial artery wall cross sectional area, mm2 |
| distensibility of the radial artery | by 2027 | ultra high frequency ultrasound radial artery distensibility coefficient in 10-3/kPa |
| elastic modulus of the radial artery | by 2027 | ultra high frequency ultrasound radial artery Young's elastic modulus, 10-3\*kPa |
| pulse wave velocity of the radial artery | by 2027 | ultra high frequency ultrasound radial artery Pulse wave velocity, m/s |
| stiffness index of the radial artery | by 2027 | ultra high frequency ultrasound radial artery Beta stiffness index |
| wall stress of the radial artery | by 2027 | ultra high frequency ultrasound radial artery Circumferential wall stress, kPa |
| pulse pressure of the radial artery | by 2027 | ultra high frequency ultrasound radial artery Pulse Pressure, mmHg |
Countries
France
Contacts
CONTACTJean-Philippe Empana, MD, PhD
CONTACTXavier Jouven, MD, PhD
PRINCIPAL_INVESTIGATORJean-Philippe Empana, MD, PhD
Institut National de la Santé Et de la Recherche Médicale, France
Outcome results
None listed